Scailyte Company

Scailyte has established a data-driven biomarker discovery platform that leverages unique expertise in single-cell data analysis and artificial intelligence. We are utilizing this platform to discover a new class of biomarkers, which are defined by the molecular profiles of disease-associated cells. This phenotypic approach to biomarker discovery is radically new and directly related to the biology of a disease, which maximizes the success rate for discovering sensitive and robust biomarkers.
Technology: Artificial Intelligence, Biotechnology, Health Diagnostics, Medical
Industry: Data Processing, Clinical Development
Headquarters: Basel, Basel-Stadt, Switzerland
Founded Date: 2017-06-19
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 6
Total Funding: 7548199
Estimated Revenue: Less than $1M
Last Funding Date: 2022-01-10
Last Funding Type: Series A

Visit Website
contact@scailyte.com
https://twitter.com/scailyte
Register and Claim Ownership